Literature DB >> 14552597

Secondary intraocular lens (IOL) implantation: anterior chamber versus scleral fixation long-term comparative evaluation.

S Dadeya1, P Kumari Sodhi.   

Abstract

PURPOSE: To compare the long-term efficacy of a secondarily implanted flexible angle supported anterior chamber (AC) intraocular lens (IOL) with sclerally fixated IOL as a secondary procedure in patients with aphakia.
METHODS: Sixty patients with aphakia were recruited for this study. The patients were randomly divided into two groups: Group I patients underwent secondary implantation with AC IOL (Kelman Z type multiflex Domi classic AC IOL) and Group II patients underwent secondary implantation with scleral fixated IOL (Hanita lens with two eyelets). Postoperatively, the patients were followed up at 1 week, monthly for 6 months, and at twice yearly intervals for 5 years (mean follow-up was 3 years).
RESULTS: Best-corrected visual acuity of 6/18 or better was achieved in 36.6% (11/30) of patients in Group I and 30% (9/30) of patients in Group II after a mean follow-up of 3 years. The complication rate was higher in Group II as compared to Group I. The authors encountered a total of 23 complications in the sclerally fixated group and 11 in the AC IOL group (p=0.004). Uveitis and ciliary tenderness were the most common complications in Groups I and II, respectively.
CONCLUSIONS: For secondary implantation of IOL in aphakic patients, Kelman Z type multiflex Domi classic AC IOL is a better rehabilitation modality as compared to the scleral fixated Hanita IOL.

Entities:  

Mesh:

Year:  2003        PMID: 14552597     DOI: 10.1177/112067210301300706

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  16 in total

1.  Primary iris claw IOL retrofixation with intravitreal triamcinolone acetonide in cases of inadequate capsular support.

Authors:  Aditya Kelkar; Rachana Shah; Viraj Vasavda; Jai Kelkar; Shreekant Kelkar
Journal:  Int Ophthalmol       Date:  2017-02-09       Impact factor: 2.031

2.  [Anterior chamber intraocular lenses for aphakia correction].

Authors:  T Kohnen; F H Hengerer
Journal:  Ophthalmologe       Date:  2014-04       Impact factor: 1.059

3.  Predictive factors of visual outcome of Malaysian cataract patients: a retrospective study.

Authors:  Thanigasalam Thevi; Myron Anthony Godinho
Journal:  Int J Ophthalmol       Date:  2017-09-18       Impact factor: 1.779

4.  Comparative study of visual outcome of newly designed scleral tuck lens and suture-fixated lens for rehabilitation of aphakia in various aetiologies.

Authors:  Mehul A Shah; Shreya M Shah; Apeksha Kataria; Rupali Baranwal; Parth Rana
Journal:  Indian J Ophthalmol       Date:  2022-06       Impact factor: 2.969

5.  Aphakia correction with retropupillary fixated iris-claw lens (Artisan) - long-term results.

Authors:  Maurice Schallenberg; Dirk Dekowski; Angela Hahn; Thomas Laube; Klaus-Peter Steuhl; Daniel Meller
Journal:  Clin Ophthalmol       Date:  2013-12-23

6.  Secondary IOL Implantation without Capsular Support: A Laser Flare Cell Meter Study.

Authors:  Mauro Cellini; Ernesto Strobbe; Pier Giorgio Toschi; Emilio C Campos
Journal:  ISRN Ophthalmol       Date:  2012-01-02

Review 7.  Iris-fixated intraocular lenses for ametropia and aphakia.

Authors:  Pedro S Simões; Tiago B Ferreira
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2014

8.  Long Term Clinical and Visual Outcomes of Retrofixated Iris Claw Lenses Implantation in Complicated Cases.

Authors:  Sri Ganesh; Sheetal Brar; Kirti Relekar
Journal:  Open Ophthalmol J       Date:  2016-04-29

9.  Long-term follow-up of retropupillary iris-claw intraocular lens implantation: a retrospective analysis.

Authors:  Matteo Forlini; Wael Soliman; Adriana Bratu; Paolo Rossini; Gian Maria Cavallini; Cesare Forlini
Journal:  BMC Ophthalmol       Date:  2015-10-27       Impact factor: 2.209

10.  Iris-claw intraocular lens implantation: Anterior chamber versus retropupillary implantation.

Authors:  Sezer Helvaci; Selahaddin Demirduzen; Huseyin Oksuz
Journal:  Indian J Ophthalmol       Date:  2016-01       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.